×

Valeant CEO talks Salix acquisition

10:48 AM ET Mon, 23 Feb 2015

Valeant will buy Salix for about $10 billion in cash. J. Michael Pearson, Valeant Pharmaceuticals CEO, discusses the deal, and the inventory issues at Salix.